Ziconotide combination intrathecal therapy for noncancer pain is limited secondary to delayed adverse effects: A case series with a 24-month follow-up

Salim M. Hayek, Michael C. Hanes, Connie Wang, I. Elias Veizi

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives The efficacy and safety of ziconotide as a single agent has been evaluated in few short-term clinical trials and open-label studies. Ziconotide use is challenging given its adverse effect (AE) profile. The objective of this study is to describe the long-term efficacy and AEs of ziconotide used as an adjunct to other intrathecal (IT) agents in chronic noncancer pain patients. Materials and Methods A case series of chronic noncancer pain patients who had suboptimal pain control from IT therapy. Ziconotide was introduced in the IT infusion mixture after a successful ziconotide trial. Pain scores, IT doses, as well as AEs were recorded and analyzed from trial to initial ziconotide infusion and up to 24 months. Results Fifteen patients underwent ziconotide trials. Four subjects failed the trial, and 11 proceeded to continuous ziconotide treatment. Seven out of 11 patients experienced AEs resulting in ziconotide discontinuation. Two of the seven subjects who required discontinuation of ziconotide had improved pain. Four subjects were able to continue IT ziconotide through 24 months. Conclusions A high incidence of AEs limits the usefulness of IT ziconotide as adjunct therapy. Our results are limited by the size of our patient population; however, they represent a long follow-up period, which is limited in most current publications on this IT peptide. While ziconotide is a needed IT agent, more studies are necessary to better understand the factors that would improve the treatment to trial ratio as well as the long-term efficacy of IT ziconotide treatment.

Original languageEnglish (US)
Pages (from-to)397-403
Number of pages7
JournalNeuromodulation
Volume18
Issue number5
DOIs
StatePublished - Jul 1 2015

Keywords

  • Adverse effects
  • intrathecal drug delivery
  • nonmalignant pain
  • ziconotide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Ziconotide combination intrathecal therapy for noncancer pain is limited secondary to delayed adverse effects: A case series with a 24-month follow-up'. Together they form a unique fingerprint.

Cite this